A Phase 2 interventional study of Bilastine 0.2% and Bilastine 0.4% in Allergic Conjunctivitis, sponsored by Faes Farma, S.A.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-16.
Sponsored by Faes Farma, S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 33rd largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2017, is one of 25 in phase 2, and was the 66th registered.
210 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 87 across 174 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Faes Farma, S.A. has 4 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilastine Ophthalmic solution 0.2% 1 drop in each eye at 3 separate times during a 25 day period.
Drug: Bilastine 0.2%
Bilastine Ophthalmic solution 0.4% 1 drop in each eye at 3 separate times during a 25 day period.
Drug: Bilastine 0.4%
Bilastine Ophthalmic solution 0.6% 1 drop in each eye at 3 separate times during a 25 day period.
Drug: Bilastine 0.6%
Vehicle of Bilastine Ophthalmic Solution 1 drop in each eye at 3 separate times during a 25 day period.
Drug: Bilastine 0%
1 drop in each eye at 3 separate times during a 25 day period.
1 drop in each eye at 3 separate times during a 25 day period.
1 drop in each eye at 3 separate times during a 25 day period.
1 drop in each eye at 3 separate times during a 25 day period.
Ocular Itching
The primary efficacy measure was ocular itching evaluated by the subject post-CAC (Conjunctival Allergen Challenge) at Visits 4b, 5b, and 6, using a 0 to 4 Ora Calibra scale: 0 = none (normal, no itching), 4 = incapacitating itch.
Time frame: The outcome measure was assessed at Visit 4b (Day 1, 16h post treatment), Visit 5b (Day 15 ±3, 8h post treatment), and Visit 6 (Day 22 ±3, 15 minutes post treatment).
| Milestone | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% |
|---|---|---|---|---|
| Started | 30 | 30 | 31 | 30 |
| Completed | 28 | 28 | 30 | 30 |
| Not completed | 2 | 2 | 1 | 0 |
The primary efficacy measure was ocular itching evaluated by the subject post-CAC (Conjunctival Allergen Challenge) at Visits 4b, 5b, and 6, using a 0 to 4 Ora Calibra scale: 0 = none (normal, no itching), 4 = incapacitating itch.
| units on a scale | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% (Vehicle) |
|---|---|---|---|---|
| Visit 4b: 3 minutes Post-CAC | 1.908 ± 0.7809 | 1.925 ± 0.9449 | 1.177 ± 1.0332 | 2.758 ± 0.7146 |
| Visit 4b: 5 minutes Post-CAC | 2.075 ± 0.7828 | 2.117 ± 0.9531 | 1.218 ± 1.1268 | 3.017 ± 0.5979 |
| Visit 4b: 7 minutes Post-CAC | 2.092 ± 0.7698 | 2.100 ± 1.0760 | 1.218 ± 1.1157 | 2.917 ± 0.5884 |
| Visit 5b: 3 minutes Post-CAC | 1.397 ± 1.1050 | 1.250 ± 0.8872 | 0.708 ± 0.8908 | 2.558 ± 0.8032 |
| Visit 5b: 5 minutes Post-CAC | 1.466 ± 0.9300 | 1.464 ± 0.9592 | 0.817 ± 1.0503 | 2.642 ± 0.7505 |
| Visit 5b: 7 minutes Post-CAC | 1.379 ± 0.8573 | 1.518 ± 1.0340 | 0.742 ± 0.9837 | 2.642 ± 0.7704 |
| Visit 6: 3 minutes Post-CAC | 0.679 ± 0.6662 | 0.732 ± 0.9127 | 0.392 ± 0.5749 | 2.542 ± 0.8384 |
| Visit 6: 5 minutes Post-CAC | 0.920 ± 0.7235 | 1.143 ± 0.9987 | 0.558 ± 0.6355 | 2.592 ± 0.8343 |
| Visit 6: 7 minutes Post-CAC | 1.000 ± 0.7454 | 1.214 ± 0.9421 | 0.583 ± 0.6706 | 2.483 ± 0.9024 |
Collected over Safety assessment period (Day 1 through Day 22). Adverts events were assessed at all office visits, throughout a period of 22 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bilastine 0.2% | 0/30 (0%) | 0/30 (0%) | 8/30 (26.7%) |
| Bilastine 0.4% | 0/30 (0%) | 0/30 (0%) | 3/30 (10%) |
| Bilastine 0.6% | 0/31 (0%) | 0/31 (0%) | 1/31 (3.2%) |
| Bilastine 0% | 0/30 (0%) | 0/30 (0%) | 7/30 (23.3%) |
| Event | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% |
|---|---|---|---|---|
| Viral Upper Respiratory Tract InfectionInfections and infestations | 1/30 | 1/30 | 0/31 | 3/30 |
| Visual Acuity ReducedEye disorders | 2/30 | 0/30 | 0/31 | 0/30 |
| BlepharitisEye disorders | 1/30 | 0/30 | 0/31 | 0/30 |
| Corneal DepositsEye disorders | 0/30 | 0/30 | 0/31 | 1/30 |
| Eye DischargeEye disorders | 0/30 | 0/30 | 0/31 | 1/30 |
| KeratitisEye disorders | 0/30 | 1/30 | 0/31 | 0/30 |
| Macular FibrosisEye disorders | 1/30 | 0/30 | 0/31 | 0/30 |
| HordeolumInfections and infestations | 1/30 | 0/30 | 0/31 | 0/30 |
| Gastroenteritis ViralInfections and infestations | 0/30 | 0/30 | 0/31 | 1/30 |
| HeadacheNervous system disorders | 0/30 | 1/30 | 0/31 | 0/30 |
| Age, Categorical(Participants) | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 28 | 27 | 27 | 27 | 109 |
| >=65 years | 2 | 3 | 4 | 3 | 12 |
| Age, Continuous(years) | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% | Total |
|---|---|---|---|---|---|
| Mean | 50.4 ± 10.7 | 47.0 ± 13.95 | 51.8 ± 13.4 | 48.3 ± 13.24 | 49.4 ± 12.8 |
| Sex: Female, Male(Participants) | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% | Total |
|---|---|---|---|---|---|
| Female | 16 | 18 | 15 | 17 | 66 |
| Male | 14 | 12 | 16 | 13 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 7 | 4 | 5 | 19 |
| Not Hispanic or Latino | 27 | 23 | 27 | 25 | 102 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 4 | 3 | 10 |
| White | 27 | 27 | 26 | 27 | 107 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% | Total |
|---|---|---|---|---|---|
| United States | 30 | 30 | 31 | 30 | 121 |
| Ocular Itching- Baseline(units on a scale) | Bilastine 0.2% | Bilastine 0.4% | Bilastine 0.6% | Bilastine 0% | Total |
|---|---|---|---|---|---|
| Visit 4b: Pre- CAC | 0.058 ± 0.2043 | 0.000 ± 0.0000 | 0.048 ± 0.1981 | 0.025 ± 0.1006 | 0.03275 ± 0.12575 |
| Visit 5b: Pre- CAC | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.033 ± 0.1826 | 0.033 ± 0.1826 | 0.0165 ± 0.0913 |
| Visit 6: Pre- CAC | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Oct 2017, 2 months.
Results were first posted in Nov 2021, 4 years 1 month after primary completion. A results delay was requested in Oct 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bilastine
Faes Farma, S.A.